Evolent Health Inc (NYSE:EVH) – KeyCorp raised their Q1 2018 earnings estimates for shares of Evolent Health in a report issued on Wednesday, Zacks Investment Research reports. KeyCorp analyst D. Hooker now anticipates that the technology company will earn ($0.02) per share for the quarter, up from their prior forecast of ($0.05). KeyCorp also issued estimates for Evolent Health’s Q2 2018 earnings at ($0.01) EPS, Q3 2018 earnings at ($0.01) EPS, FY2018 earnings at ($0.05) EPS and FY2019 earnings at $0.18 EPS.
A number of other research firms have also issued reports on EVH. Cowen restated an “outperform” rating and set a $29.00 price target (down previously from $33.00) on shares of Evolent Health in a report on Friday, October 6th. SunTrust Banks restated a “buy” rating and set a $30.00 price target on shares of Evolent Health in a report on Friday, November 3rd. Leerink Swann set a $25.00 price objective on shares of Evolent Health and gave the company a “buy” rating in a research report on Saturday, November 18th. Robert W. Baird reissued a “buy” rating and issued a $25.00 target price on shares of Evolent Health in a research report on Wednesday, November 1st. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $30.00 target price on shares of Evolent Health in a research report on Sunday, December 3rd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $28.00.
Evolent Health (EVH) traded up $0.30 during midday trading on Monday, hitting $14.50. 672,100 shares of the company were exchanged, compared to its average volume of 1,192,843. Evolent Health has a twelve month low of $10.30 and a twelve month high of $27.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.34 and a quick ratio of 3.34. The company has a market cap of $1,120.00 and a P/E ratio of -12.72.
Evolent Health (NYSE:EVH) last released its earnings results on Thursday, November 2nd. The technology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The business had revenue of $107.90 million for the quarter, compared to the consensus estimate of $104.49 million. During the same period in the previous year, the firm earned ($0.26) EPS. The business’s revenue for the quarter was up 79.2% on a year-over-year basis.
Several hedge funds have recently made changes to their positions in EVH. ETF Managers Group LLC bought a new stake in Evolent Health during the 2nd quarter worth about $102,000. BNP Paribas Arbitrage SA raised its position in shares of Evolent Health by 815.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock valued at $120,000 after acquiring an additional 4,232 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Evolent Health in the 3rd quarter valued at approximately $156,000. Fox Run Management L.L.C. acquired a new stake in shares of Evolent Health in the 4th quarter valued at approximately $175,000. Finally, IPG Investment Advisors LLC acquired a new stake in Evolent Health during the 3rd quarter worth approximately $195,000. Institutional investors own 95.42% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Evolent Health Inc (NYSE:EVH) to Post Q1 2018 Earnings of ($0.02) Per Share, KeyCorp Forecasts” was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.truebluetribune.com/2018/01/23/evolent-health-inc-evh-to-post-q1-2018-earnings-of-0-02-per-share-keycorp-forecasts.html.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.